A4061079
: Phase 1b
dose‐finding
study of pembrolizumab + axitinib in 1
st
line mRCC
A4061079: Phase 1b dose‐finding study of pembrolizumab + axit nib in
1
st
line mRCC
•
Combination axitinib plus pembrolizumab exhibits antitumor activity with acceptable toxicity profile ‐ no
Atkins
et al
. ESMO 2016 Poster 773PD
new or unusual toxicities were observed‐ in treatment‐naïve patients with advanced RCC
•
Few treatment discontinuations due to hepatotoxicity
•
PD‐L1 status did not predict tumor response
•
PFS, overall survival, and response duration data are not mature
